Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myeloid, Acute 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Large B-Cell, Diffuse 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Multiple Myeloma 2Lymphoma, Follicular 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Hepatoblastoma 2Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Wilms Tumor 1Uveal Melanoma 1Skin Neoplasms 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Malignant Peripheral Nerve Sheath Tumors 1Ototoxicity 1Oligodendroglioma 1Neoplasm Metastasis 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Cyclophosphamide 47Rituximab 31fludarabine 29Specimen Handling 13Magnetic Resonance Spectroscopy 13Doxorubicin 13pirtobrutinib 11Vincristine 11Prednisone 11fludarabine phosphate 10Immunotherapy, Adoptive 10Etoposide 10Bendamustine Hydrochloride 10obinutuzumab 8Lenalidomide 8Biopsy 8venetoclax 7polatuzumab vedotin 7glofitamab 7zanubrutinib 6pembrolizumab 6Dexamethasone 6tafasitamab 5ibrutinib 5etoposide phosphate 5acalabrutinib 5Leukapheresis 5tazemetostat 4loncastuximab tesirine 4Nivolumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell × Vorinostat × 1 year × Clear all
NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

City of Hope Medical Center

Phase 1 Active not recruiting
52 enrolled 13 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡